Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
41.37
-2.28 (-5.22%)
At close: Nov 20, 2026, 4:00 PM EST
41.40
+0.03 (0.07%)
After-hours: Nov 20, 2026, 7:30 PM EST
Arrowhead Pharmaceuticals Revenue
In the fiscal year ending September 30, 2026, Arrowhead Pharmaceuticals had annual revenue of $450.82M, down -45.65%. Arrowhead Pharmaceuticals had revenue of $37.79M in the quarter ending September 30, 2026, a decrease of -85.26%. That makes Arrowhead Pharmaceuticals the 11,868th largest company in the world by revenue and 2,355th in the United States.
Revenue (ttm)
$450.82M
Revenue Growth
-45.65%
P/S Ratio
12.97
Revenue / Employee
$424,498
Employees
1,062
Market Cap
5.85B
Revenue by Segment
- Sarepta 316.89M 70.3%
- Novartis 89.01M 19.7%
- Madrigal 25.00M 5.5%
- Sanofi 13.32M 3.0%
- Product 6.60M 1.5%
Fiscal year ended Sep 30, 2026 See the full Arrowhead Pharmaceuticals breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2026 | 450.82M | -378.63M | -45.65% |
| Sep 30, 2025 | 829.45M | 825.90M | 23,258.15% |
| Sep 30, 2024 | 3.55M | -237.18M | -98.52% |
| Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
| Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
| Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
| Sep 30, 2020 | 87.99M | -80.80M | -47.87% |
| Sep 30, 2019 | 168.80M | 152.65M | 945.67% |
| Sep 30, 2018 | 16.14M | -15.27M | -48.60% |
| Sep 30, 2017 | 31.41M | 31.25M | 19,736.49% |
| Sep 30, 2016 | 158.33K | -223.67K | -58.55% |
| Sep 30, 2015 | 382.00K | 207.00K | 118.29% |
| Sep 30, 2014 | 175.00K | -115.27K | -39.71% |
| Sep 30, 2013 | 290.27K | 143.39K | 97.63% |
| Sep 30, 2012 | 146.88K | -149.26K | -50.40% |
| Sep 30, 2011 | 296.14K | - | - |
| Sep 30, 2010 | - | - | - |
| Sep 30, 2009 | 3.76M | 2.45M | 188.38% |
| Sep 30, 2008 | 1.30M | 95.18K | 7.88% |
| Sep 30, 2007 | 1.21M | 746.74K | 161.88% |
| Sep 30, 2006 | 461.28K | -129.40K | -21.91% |
| Sep 30, 2005 | 590.68K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Corcept Therapeutics | 963.65M |
| Axsome Therapeutics | 865.27M |
| Mirum Pharmaceuticals | 670.78M |
| Ligand Pharmaceuticals | 253.83M |
| ImmunityBio | 182.57M |
| ABIVAX Société Anonyme | 5.33M |
| Scholar Rock Holding | 570.00K |
ARWR News
- 4 days ago - Arrowhead Pharmaceuticals Transcript: Jefferies Global Healthcare Conference - Transcripts
- 4 days ago - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 5 days ago - Arrowhead price target lowered to $105 from $108 at Citi - TheFly
- 8 days ago - Arrowhead price target lowered to $106 from $120 at Morgan Stanley - TheFly
- 9 days ago - Arrowhead price target lowered to $96 from $104 at Stifel - TheFly
- 9 days ago - Arrowhead Pharmaceuticals Earnings Call Transcript: Q4 2026 - Transcripts
- 9 days ago - Arrowhead Pharmaceuticals Earnings release: Q4 2026 - Filings
- 9 days ago - Arrowhead Pharmaceuticals Annual report: Q4 2026 - Filings